Table 3.
Prognostic factors in multivariate analysis
| Characteristic | Intrathoracic-PFS |
PFS |
OS |
|||
|---|---|---|---|---|---|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value | HR (95% CI) | p-value | |
| Age (yr) | 0.871 | 0.834 | 0.450 | |||
| ≤65 | 1 | 1 | 1 | |||
| >65 | 1.053 (0.565–1.962) | 1.057 (0.629–1.776) | 1.230 (0.719–2.105) | |||
| Sex | 0.244 | 0.181 | 0.114 | |||
| Male | 1.887 (0.649–5.485) | 1.725 (0.776–3.833) | 1.612 (0.708–3.674) | |||
| Female | 1 | 1 | 1 | |||
| ECOG performance status | ||||||
| 0–1 | 1 | 1 | 1 | |||
| ≥2 | 0.715 (0.353–1.450) | 0.917 (0.525–1.602) | 1.355 (0.786–2.335) | |||
| Smoking | 0.267 | 0.716 | 0.559 | |||
| No | 1 | 1 | 1 | |||
| Yes | 1.884 (0.616–5.760) | 1.163 (0.516–2.620) | 1.275 (0.565–2.877) | |||
| Extrathoracic lesion in liver | 0.993 | 0.710 | 0.406 | |||
| No | 1 | 1 | 1 | |||
| Yes | 0.995 (0.326–3.034) | 0.830 (0.311–2.218) | 1.407 (0.628–3.151) | |||
| Dose (BED) | 0.001 | 0.004 | 0.015 | |||
| ≤50 Gy10 | 1 | 1 | 1 | |||
| >50 Gy10 | 0.331 (0.171–0.641) | 0.453 (0.265–0.773) | 0.502 (0.287–0.876) | |||
| PCI | 0.168 | 0.338 | 0.321 | |||
| No | 1 | 1 | 1 | |||
| Yes | 0.557 (0.242–1.281) | 0.699 (0.336–1.454) | 0.710 (0.361–1.396) | |||
| Response to the last chemotherapy | 0.818 | 0.395 | 0.049 | |||
| Partial response/stable disease | 1.078 (0.568–2.045) | 0.790 (0.459–1.359) | 0.554 (0.308–0.998) | |||
| Progressive disease | 1 | 1 | 1 | |||
PFS, progression-free survival; OS, overall survival; ECOG, Eastern Cooperative Oncology Group; BED, biological effective dose; PCI, prophylactic cranial irradiation.